Cross-linking stability remarkable

Article

Corneal crosslinking showed remarkable stability in a recent rabbit study, Dr Gregor Wollensak told delegates during the session on New Surgical Approaches to Keratoconus.

Corneal crosslinking showed remarkable stability in a recent rabbit study, Dr Gregor Wollensak told delegates during the session on New Surgical Approaches to Keratoconus.

"There are good prospects for the long-term stability of the technique, which is of course underlined by the very promising results from the Dresden five-year study, " he said.

Dr Wollensak outlined the biomechanical characteristics of the cornea after collagen crosslinking. "What is crosslinking in every day experience? " he asked. "Age-related crosslinking is where the meat of young animals is soft and tender whereas the meat of older animals is tough. "

Cataract, he said, was an example of crosslinking within the crystalline lens and that chemical crosslinking is demonstrated with formalin-induced hardening in tissue fixation.

He said this was a useful phenomenon in keratoconus because tensile strength of the cornea is reduced about 36% in that condition.

He outlined the standard procedure and told delegates: "So far, so good, but there are two outstanding questions that remain unanswered: What about C3-R? What about long-term stability of the biomechanical effect? "

He explained that C3-R (corneal collagen crosslinking with riboflavin) was introduced in 2004 by Dr. Boxer Wachler to reduce postoperative pain. It uses preoperative anaesthetic eye drops containing benzalkoniumchloride (BAK). This loosens up the tight junctions of the corneal epithelial cells thus allowing transepithelial crosslinking treatment without removal of the epithelium.

Dr Wollensak designed a rabbit experiment to test the efficacy of C3-R against standard corneal crosslinking. Group 1 (corneal crosslinking, n=5) had epithelial debridement, conjuncain and standard riboflavin solution starting 10 min before irradiation.

Group 2 (C3-R; n=5) had no debridement and proparacaine anaesthetic containing BAK starting 30 min before irradiation. Group 3 (C3-R without BAK; n=4) had no debridement, received conjuncaine without BAK 30 min before irradiation.

Results showed that corneal crosslinking had a marked effect on collagen hardening, while C3-R with BAK demonstrated one-fifth of the effect, while C3-R had actually reduced hardness in the cornea.

Dr Wollensak said that human corneas demonstrated a greater crosslinking effect than rabbits, by a factor of 2.5 "A higher degree of natural baseline crosslinking in rabbit cornea means there is more potential for an increase in crosslinking in the human cornea, " he said.

He said in human corneas the result of the rabbit experiment would probably correspond to 65% increase in corneal hardening by C3-R (320% by corneal crosslinking). "On histology, there was only toxicity down to 200 µm. So, C3-R can be recommended for thin corneas due to lower toxicity, but not for routine crosslinking, " Dr Wollensak said.

He also studied the stability of the effect in rabbits, testing the collagen crosslinking effect at one day, three months and eight months.

He said that the long term stability of the biomechanical effect of corneal crosslinking over eight months was remarkable. "Corneal collagen turnover rate is probably very slow like in the tendon or skin, so there are excellent prospects for the stability of corneal crosslinking. "

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.